|
Pantothenic Acid
|
D02.478.520 |
|
|
Erythema Infectiosum
|
C17.800.838.790.260 |
|
|
Skin Diseases, Viral
|
C17.800.838.790 |
|
|
Measles-Mumps-Rubella Vaccine
|
D20.215.894.899.488.500 |
|
|
Receptor-Interacting Protein Serine-Threonine Kinase 2
|
D12.776.476.075.358.750 |
|
|
Ubiquitin-Specific Peptidase 7
|
D08.811.037.750.750 |
|
|
Hepatitis, Viral, Human
|
C06.552.380.705 |
|
|
Hepatitis
|
C06.552.380 |
|
|
Mycoplasma bovis
|
B03.440.860.580.553.553.200 |
|
|
Nitroarginine
|
D12.125.095.104.587 |
|
|
Buspirone
|
D02.455.426.779.120 |
|
|
Cefotetan
|
D03.383.129.617.235 |
|
|
Theranostic Nanomedicine
|
D000068936 |
[An integrated nano-scale approach to MEDICINE which involves concurrent diagnosis, drug delivery, therapy, and monitoring of therapeutic response.
] |
|
Interferon Regulatory Factor-7
|
D12.776.476.024.385.437 |
|
|
Cosmeceuticals
|
D000068937 |
[COSMETICS that are associated with therapeutic effects.
] |
|
Hearing Loss, Sensorineural
|
D006319 |
[Hearing loss resulting from damage to the COCHLEA and the sensorineural elements which lie internally beyond the oval and round windows. These elements include the AUDITORY NERVE and its connections in the BRAINSTEM.
] |
|
Hearing Loss, Conductive
|
D006314 |
[Hearing loss due to interference with the mechanical reception or amplification of sound to the COCHLEA. The interference is in the outer or middle ear involving the EAR CANAL; TYMPANIC MEMBRANE; or EAR OSSICLES.
] |
|
Hearing Loss, Functional
|
D006315 |
[Hearing loss without a physical basis. Often observed in patients with psychological or behavioral disorders.
] |
|
Elafin
|
D12.644.822.437 |
|
|
Hearing Loss, High-Frequency
|
D006316 |
[Hearing loss in frequencies above 1000 hertz.
] |
